Minimising risks: drug discovery practices for Chief Scientific Officers
Posted 2nd February 2010 in Articles, R&D | 3 comments
pharmaphorum invites feedback from our readers on the recent interview marcus evans conducted with Malcolm Weir, CEO of Heptares Therapeutics, discussing the challenges of drug discovery today.
Statistics seem almost stacked against developing a fitting drug for a target disease. Drug discovery is plagued by time consuming and costly…
Read the full articleDifficult issues in pharma going global (part II)
Posted 14th January 2010 in Articles, R&D | 1 comment
In the concluding part of this two part article, Faiz Kermani explores regulations to control trials in emerging markets and asks whether pharma is being ethical enough in these regions.
In the first part of this article I looked at the growth of clinical development activity in the emerging pharma markets…
Read the full articleDifficult issues in pharma going global (part I)
Posted 12th January 2010 in Articles, R&D | 2 comments
In the first piece of a two part article, Faiz Kermani looks at the emergence of clinical trial activity in emerging markets and explores some of the ethical issues.
Although the economic downturn has had a negative impact, the global pharmaceutical market is still experiencing strong growth…
Read the full articleA ghostly undertaking
Posted 24th November 2009 in Articles, R&D | 3 comments
As medical ghostwriting comes under increasing scrutiny, Les Rose asks whether the ability to communicate in writing should not be a specialism in its own right.
Many years ago I was the project manager of a large clinical study. I ran the study, did most of the data management and a good deal of the analysis, and then left the company for pastures new. Someone else came on board and wrote up the results…
Read the full article